Funding for this research was provided by:
Indiana Clinical and Translational Sciences Institute (UL1TR001108)
Received: 1 April 2020
Accepted: 7 November 2020
First Online: 7 January 2021
Ethics approval and consent to participate
: All in vivo experiments were approved by the Purdue University Animal Care and Use Committee.
: All authors read and approved the final manuscript.
: Riyi Shi is the co-founder of Neuro Vigor, a start-up company with business interests of developing effective therapies for CNS neurodegenerative diseases and trauma. The remaining authors declare no competing interests.